Skip to content
Announcement:

Latest Publication: Read our teams’ latest paper in Antibiotics, showing reduced nephrotoxicity of a novel formulation of polymyxin B compared to the clinical formulation using a validated primary human proximal tubule cell model.

5th Chronic Kidney Disease Drug Development Summit

Date

7th March 2023 - 9 March, 2023

Location

Boston, MA

Venue

Hilton Boston Logan Airport Hotel

Presented by

Dr Kathryn Garner

The CKD Drug Development Summit is uniquely positioned to de-risk drug development in cardiorenal disorders and provide strategic insight into paving the way to regulatory approval.

Dr Kathryn Garner will be presenting the following talk:

Primary kidney cells for modelling Chronic Kidney Disease in vitro

• Human podocytes maintain high levels of key podocyte markers, including nephrin, podocin, WT1, CD2AP.
• Well-validated Podocyte Toxicity Assay senses injury through barrier integrity (TEER) measures and passage of fluorescently-labelled dextran molecules.
• Disease modelling in podocytes, proximal tubule cells and renal fibroblasts with monitoring of fibrosis readouts – matrix deposition – using high content imaging.

Discover more about our glomerulus model

Find out more

Share on social media:

Don't miss out on our latest innovations: follow us on Linkedin

Get our latest updates straight to your inbox